Clinical Trial Search

Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants

Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants

Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Safety - Occurrence of Adverse Events — 7; 21; 19; 20 Number of Adverse Events

Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Blood Test Performance — 18; 17 Participants

Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants

Primary: Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs…

Primary: Duration of Diarrhea — 2; 2 days — p=0.43

Primary: Participants Experiencing Fever, Diarrhea, or Dysentery; Solicited Local Adverse Events; Solicited Systemic Adverse Events; and Clinical Safety Laboratory Adverse Events…

Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc

Primary: Development of Diarrhea — 5; 6 participants

Primary: Number of Participants With Modified Vesikari Scale Score >=9 — 55; 60 Participants — p=0.83

Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941

Primary: Number of Patients Diagnosed With Hirschsprung-associated Enterocolitis (HAEC). — 10; 7 participants — p==0.897

Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254

Primary: Treatment Failure — 23; 101 Treatment success

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88

Primary: Time to Last Unformed Stool (TLUS) — 37.4; 21.; 68; 46 TLUS (hours)

Primary: Presence of Fecal Shedding of Polio Vaccine Virus Determined by Culture (Polio Trial) — 99; 109 Participants — p=0.4

Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003

Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants

Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932

Primary: Salivary EGF (Epidermal Growth Factor) Protein Levels — 15 picograms EGF/ microgram of protein